Regulatory Filings • Nov 13, 2025
Preview not available for this file type.
Download Source FileField: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
November 13, 2025
Date of Report (date of earliest event reported)
Bio Green Med Solution, Inc.
(Exact name of Registrant as specified in its charter)
| Delaware | 0-50626 | 91-1707622 |
|---|---|---|
| (State | ||
| or other jurisdiction of incorporation | ||
| or organization) | (Commission File | |
| Number) | (I.R.S. | |
| Employer Identification | ||
| Number) |
Level 10, Tower 11 , Avenue 5, No. 8
Jalan Kerinchi , Kuala Lumpur , Malaysia 59200
(Address of principal executive offices) (Zip code)
(908) 517-7330
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.001 per share | BGMS | The Nasdaq Capital Market |
| Preferred
Stock, $0.001 par value | BGMSP | The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
Item 2.02. Results of Operations and Financial Condition.
and
Item 7.01. Regulation FD Disclosure.
The following information is being furnished pursuant to Item 2.02, “Results of Operations and Financial Condition” and Item 7.01, “Regulation FD Disclosure”, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On November 13, 2025, Bio Green Med Solution Inc. issued a press release setting forth its third quarter 2025 results. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
| Exhibit
No. | Exhibit |
| --- | --- |
| 99.1 | Press Release of Bio Green Med Solution, Inc. dated November 13, 2025. |
| 104 | Cover
Page Interactive Data File (embedded within the XBRL document) |
Field: Page; Sequence: 2
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date:
November 13, 2025 | |
| --- | --- |
| By: | /s/
Datuk Dr. Doris Wong Sing Ee |
| Name: | Datuk
Dr. Doris Wong Sing Ee |
| Title: | Chief
Executive Officer and Executive Director |
Field: Page; Sequence: 3; Options: Last
Field: /Page
Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kU1uwjAQRk/AHUZRlwhsV3SRXRtRVDVUESDUrSFDa5F4orFJ4Ui9ZR2noRtqWbJsf2+ef5JknCzo2VTI8P60ymGDdVNpj7DCAzLaPYZE9vKaQhhX+GGcZ219nA5gRoHBwDxM1C6sx2RrHJYpSDmV91M1A6nSmYRimYy6/YzswZRovdEVaFtCwdSwQa/50lfY6DNZqi/RtEV2hmwoNxH99jcoIRW8Uau/iI8O8jxLRuPYRsmC6dSE1Pzs0XYkzCusg8719F+Pp9mfnKc6Lbi7M2O59rQ/iokQstC81dUJl1jvkENUCqWkePw9xZWAiIzhLlLQaIa2425YwmvVZGN+qN6rkNefmv9T9djguQquxvAPrsMH4w+iFIry
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.